News

Preclinical data shows the potential of oxMIF as a new immuno-oncology target which may be helpful in treating patients with metastatic colorectal cancers

After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.

Fadi Haddad, MD, discusses the key points from the presentation he gave during the Tenth Annual Meeting of the Society of Hematologic Oncology.

With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.

In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.

Results from the phase 3 KEYNOTE-859 study show extended overall and progression-free survival in patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma treated with pembrolizumab and chemotherapy.

Matthew Ingham, MD, discusses understanding the genomics of sarcomas and how molecular testing can be useful in this space.

Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.

Additional data is needed for lifileucel before it is granted a biologics license application by the FDA for patients with unresectable or metastatic melanoma.

Florida Cancer Specialists & Research Institute welcomes Board-certified medical oncologist Ke Ning, MD to the Sarasota Downtown clinic team.

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed managing patients with different subtypes of ALL and the session he was a part of during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.

Erika P. Hamilton, MD, discusses the key safety and efficacy findings from the phase 3 DESTINY-Breast03 study.

In an interview with Targeted Oncology, Karie Runcie, MD, provided an assessment on the Clavien-Dindo classification system and discussed initial results of the Cyo-KIK trial.

Updated data from the phase 3 CheckMate 9LA trial showed that the combination of nivolumab, ipilimumab, and 2 cycles of chemotherapy elicited survival benefit in patients with treatment-naïve metastatic non–small cell lung cancer.

An analysis of data from 2002-2015 shows that for patients with mantle cell lymphoma achieving event-free survival after two years may be a prognostic factor for better overall survival outcomes.

The FDA has approved a new dosing schedule of Rylaze for patients with acute lymphoblastic leukemia and lymphoblastic lymphoma.

DCVax-L was well tolerated and prolonged survival in patients with newly diagnosed and recurrent glioblastoma within the phase 3 trial.

An investigational agent is planned for a phase 1 trial of patients with mantle cell lymphoma after preclinical data showed antitumor activity.

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.

In patients with non–small cell lung cancer who harbor an EGFR exon 20 insertion mutation, sunvozertinib demonstrated promising efficacy.

Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.

Updated results of the EMPOWER-Lung1 trial of cemiplimab in patients advanced or metastatic non–small cell lung cancer showed improvements in overall survival, progression-free survival, and overall response rate.

Fifty percent of patients with advanced soft tissue sarcoma enrolled in the phase 1b study of camsirubicin and pegfilgrastim had stable disease.

Tepotinib was able to provide clinically meaningful activity in patients with high MET amplification non–small cell lung cancer in the VISION study, according to Xiuning Le, MD, PhD.

Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.

The combination of ivuxolimab and utomilumab was well tolerated in patients with advanced solid tumors, according to a phase 1 study.

In an interview with Targeted Oncology, Nagaraj Nagathihalli, PhD, further explained the basis behind his study examining tobacco-associated pancreatic cancer and his plans to improve overall survival in this patient population.

Eytan M. Stein, MD, discusses the currently available treatment options for patients with acute myeloid leukemia and how Menin inhibitors fit into this space.

Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.

While information has come out stating the negative effects of e-cigarettes on lung health, questions regarding the longer-term safety of these products remain due to their limited timespan on the market.